Who
Gilla Kaplan
Director
Company insider
Files Form 4 as: Director, Avalo Therapeutics; Director, Tyra Biosciences; Director, Celgene Corp /de/.
In numbers
- Trades disclosed
- 190
- Buys
- 0
- Sells
- 32
- Bought
- $0
- Sold
- $53.3M
- Companies
- 3
- Companies where not an officer
- 3
- First trade
- 30 Oct 2006
- Last trade
- 2 Jun 2026
- Last filed
- 4 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 2 Jun 2026filed 4 Jun 2026 | AVTX Avalo Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,100 at $0.00 | filing |
| 2 Jun 2026filed 4 Jun 2026 | AVTX Avalo Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,100 at $0.00 | filing |
| 28 Mar 2026filed 31 Mar 2026 | AVTX Avalo TherapeuticsBiotechnology | SEC FORM 4 Code M | —3,166 | filing |
| 28 Mar 2026filed 31 Mar 2026 | AVTX Avalo Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,166 at $0.00 | filing |
| 28 Mar 2026filed 31 Mar 2026 | AVTX Avalo Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,166 at $0.00 | filing |
| 28 Mar 2026filed 31 Mar 2026 | AVTX Avalo TherapeuticsBiotechnology | SEC FORM 4 Code M | —3,166 | filing |
| 26 Mar 2026filed 27 Mar 2026 | TYRA Tyra BiosciencesBiotechnology | SEC FORM 4 Code M | $120K53,172 at $2.25 | filing |
| 26 Mar 2026filed 27 Mar 2026 | TYRA Tyra Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code M | —53,172 at $0.00 | filing |
| 26 Mar 2026filed 27 Mar 2026 | TYRA Tyra BiosciencesBiotechnology | SEC FORM 4 Code D | $2.0M53,172 at $37.75 | filing |
| 26 Mar 2026filed 27 Mar 2026 | TYRA Tyra Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code M | —53,172 at $0.00 | filing |
| 26 Mar 2026filed 27 Mar 2026 | TYRA Tyra BiosciencesBiotechnology | SEC FORM 4 Code M | $120K53,172 at $2.25 | filing |
| 26 Mar 2026filed 27 Mar 2026 | TYRA Tyra BiosciencesBiotechnology | SEC FORM 4 Code D | $2.0M53,172 at $37.75 | filing |
| 25 Mar 2026filed 27 Mar 2026 | TYRA Tyra BiosciencesBiotechnology | SEC FORM 4 Code M | $32K14,295 at $2.25 | filing |
| 25 Mar 2026filed 27 Mar 2026 | TYRA Tyra BiosciencesBiotechnology | SEC FORM 4 Sold | $529K14,295 at $36.97 | filing |
| 25 Mar 2026filed 27 Mar 2026 | TYRA Tyra Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code M | —14,295 at $0.00 | filing |
| 25 Mar 2026filed 27 Mar 2026 | TYRA Tyra Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code M | —14,295 at $0.00 | filing |
| 25 Mar 2026filed 27 Mar 2026 | TYRA Tyra BiosciencesBiotechnology | SEC FORM 4 Code M | $32K14,295 at $2.25 | filing |
| 25 Mar 2026filed 27 Mar 2026 | TYRA Tyra BiosciencesBiotechnology | SEC FORM 4 Sold | $528K14,295 at $36.97 | filing |
| 18 Jun 2025filed 20 Jun 2025 | TYRA Tyra BiosciencesBiotechnology | SEC FORM 4 Sold | $94K9,568 at $9.78 | filing |
| 17 Jun 2025filed 20 Jun 2025 | TYRA Tyra BiosciencesBiotechnology | SEC FORM 4 Sold | $10410 at $10.35 | filing |
News
No headline names them, or the companies they trade most, lately.